Susanne Stowasser

15.8k total citations · 8 hit papers
118 papers, 6.8k citations indexed

About

Susanne Stowasser is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, Susanne Stowasser has authored 118 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Pulmonary and Respiratory Medicine, 28 papers in Physiology and 20 papers in Pathology and Forensic Medicine. Recurrent topics in Susanne Stowasser's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (112 papers), Sarcoidosis and Beryllium Toxicity Research (27 papers) and Systemic Sclerosis and Related Diseases (20 papers). Susanne Stowasser is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (112 papers), Sarcoidosis and Beryllium Toxicity Research (27 papers) and Systemic Sclerosis and Related Diseases (20 papers). Susanne Stowasser collaborates with scholars based in Germany, United States and France. Susanne Stowasser's co-authors include Martin Kolb, Luca Richeldi, Manuel Quaresma, Ganesh Raghu, Vincent Cottin, Rozsa Schlenker‐Herceg, Toby M. Maher, Lutz Wollin, Emmanuelle Clerisme-Beaty and Kay Tetzlaff and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Susanne Stowasser

108 papers receiving 6.6k citations

Hit Papers

Nintedanib in Progressive... 2015 2026 2018 2022 2019 2019 2015 2016 2019 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
    2019 1.3k citations Kevin R. Flaherty, Athol U. Wells et al. New England Journal of Medicine profile →
  2. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
    2019 956 citations Arata Azuma, Ganesh Raghu et al. New England Journal of Medicine profile →
  3. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
    2015 698 citations Susanne Stowasser, Martin Kolb et al. European Respiratory Journal profile →
  4. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
    2016 330 citations Luca Richeldi, Vincent Cottin et al. Respiratory Medicine profile →
  5. Fibrosing interstitial lung diseases: knowns and unknowns
    2019 215 citations Vincent Cottin, Manuel Quaresma et al. profile →
  6. Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
    2022 139 citations Luca Richeldi, Arata Azuma et al. New England Journal of Medicine profile →
  7. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
    2025 28 citations Luca Richeldi, Arata Azuma et al. New England Journal of Medicine profile →
  8. Nerandomilast in Patients with Progressive Pulmonary Fibrosis
    2025 19 citations Toby M. Maher, Shervin Assassi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susanne Stowasser Germany 31 6.1k 2.4k 1.6k 943 903 118 6.8k
Rozsa Schlenker‐Herceg United States 22 3.5k 0.6× 2.1k 0.9× 691 0.4× 570 0.6× 518 0.6× 47 4.1k
Carlo Albera Italy 16 3.9k 0.6× 1.4k 0.6× 270 0.2× 506 0.5× 545 0.6× 48 4.2k
Philippe Casassus France 30 1.7k 0.3× 654 0.3× 604 0.4× 292 0.3× 1.1k 1.2× 80 6.1k
John L. Niles United States 34 2.5k 0.4× 857 0.4× 260 0.2× 257 0.3× 1.0k 1.1× 85 3.8k
Masato Karayama Japan 27 1.3k 0.2× 557 0.2× 180 0.1× 443 0.5× 184 0.2× 163 2.2k
Jan‐Stephan Sanders Netherlands 34 1.2k 0.2× 270 0.1× 264 0.2× 241 0.3× 430 0.5× 168 4.2k
J.H.J.M. van Krieken Netherlands 20 1.3k 0.2× 834 0.3× 475 0.3× 323 0.3× 85 0.1× 33 3.5k
Kazuo Kasahara Japan 32 2.5k 0.4× 546 0.2× 248 0.2× 310 0.3× 99 0.1× 255 3.7k
Toshiaki Morikawa Japan 36 2.3k 0.4× 325 0.1× 271 0.2× 856 0.9× 201 0.2× 204 4.9k
James B. Whitmore United States 25 726 0.1× 624 0.3× 174 0.1× 191 0.2× 749 0.8× 63 4.0k

Countries citing papers authored by Susanne Stowasser

Since Specialization
Citations

This map shows the geographic impact of Susanne Stowasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susanne Stowasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susanne Stowasser more than expected).

Fields of papers citing papers by Susanne Stowasser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susanne Stowasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susanne Stowasser. The network helps show where Susanne Stowasser may publish in the future.

Co-authorship network of co-authors of Susanne Stowasser

This figure shows the co-authorship network connecting the top 25 collaborators of Susanne Stowasser. A scholar is included among the top collaborators of Susanne Stowasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susanne Stowasser. Susanne Stowasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Richeldi, Luca, Arata Azuma, Vincent Cottin, et al.. (2025). Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 392(22). 2193–2202. 28 indexed citations breakdown →
2.
Hartmann, Sylvia, et al.. (2025). Exposure‐Efficacy Meta‐Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases. CPT Pharmacometrics & Systems Pharmacology. 15(1). e70132–e70132.
3.
Richeldi, Luca, Arata Azuma, Vincent Cottin, et al.. (2025). Initiation of Supplemental Oxygen in the FIBRONEER-IPF Trial of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A7047–A7047.
4.
Maher, Toby M., Shervin Assassi, Arata Azuma, et al.. (2025). Nerandomilast in Patients with Progressive Pulmonary Fibrosis. New England Journal of Medicine. 392(22). 2203–2214. 19 indexed citations breakdown →
5.
Maher, Toby M., Gísli Jenkins, Vincent Cottin, et al.. (2024). Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial. ERJ Open Research. 10(4). 335–2023. 3 indexed citations
6.
Maher, Toby M., Susanne Stowasser, Florian Voß, et al.. (2023). Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis. Respirology. 28(12). 1147–1153. 16 indexed citations
7.
Brown, Kevin K., Yoshikazu Inoue, Kevin R. Flaherty, et al.. (2022). Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology. 27(4). 294–300. 29 indexed citations
8.
Flaherty, Kevin R., Athol U. Wells, Vincent Cottin, et al.. (2021). Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. European Respiratory Journal. 59(3). 2004538–2004538. 65 indexed citations
9.
10.
11.
Kreuter, Michael, Wim Wuyts, Marlies Wijsenbeek, et al.. (2020). Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials. Respiratory Research. 21(1). 36–36. 32 indexed citations
12.
Song, Jin Woo, Takashi Ogura, Yoshikazu Inoue, et al.. (2019). Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON. Respirology. 25(4). 410–416. 30 indexed citations
13.
Behr, Jürgen, Martin Kolb, Jin Woo Song, et al.. (2019). Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). American Journal of Respiratory and Critical Care Medicine. 200(12). 1505–1512. 49 indexed citations
14.
Flaherty, Kevin R., Athol U. Wells, Vincent Cottin, et al.. (2019). Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine. 381(18). 1718–1727. 1333 indexed citations breakdown →
15.
Richeldi, Luca, Bruno Crestani, Arata Azuma, et al.. (2019). Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. Respiratory Medicine. 156. 20–25. 19 indexed citations
16.
Brown, Kevin M., Kevin R. Flaherty, Vincent Cottin, et al.. (2018). Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine. 146. 42–48. 26 indexed citations
17.
Vancheri, Carlo, Michael Kreuter, Luca Richeldi, et al.. (2017). Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine. 197(3). 356–363. 208 indexed citations
18.
Raghu, Ganesh, Athol U. Wells, Andrew G. Nicholson, et al.. (2016). Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. American Journal of Respiratory and Critical Care Medicine. 195(1). 78–85. 127 indexed citations
19.
Costabel, Ulrich, Yoshikazu Inoue, Luca Richeldi, et al.. (2015). Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. American Journal of Respiratory and Critical Care Medicine. 193(2). 178–185. 193 indexed citations
20.
Cottin, Vincent, Hiroyuki Taniguchi, Harold R. Collard, et al.. (2014). Reduction in disease progression with nintedanib in the INPULSIS™ trials. European Respiratory Journal. 44(Suppl 58). 1906–1906. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rozsa Schlenker‐Herceg Breakdown of academic impact, for papers by Carlo Albera Breakdown of academic impact, for papers by Philippe Casassus Breakdown of academic impact, for papers by John L. Niles Breakdown of academic impact, for papers by Masato Karayama Breakdown of academic impact, for papers by Jan‐Stephan Sanders Breakdown of academic impact, for papers by J.H.J.M. van Krieken Breakdown of academic impact, for papers by Kazuo Kasahara Breakdown of academic impact, for papers by Toshiaki Morikawa Breakdown of academic impact, for papers by James B. Whitmore
Rankless by CCL
2026